Recent progress in developing of thrombolytic agents for ischemic stroke / 生物工程学报
Chinese Journal of Biotechnology
;
(12): 2029-2039, 2020.
Artículo
en Chino
| WPRIM
| ID: wpr-878463
ABSTRACT
Ischemic stroke is a major health crisis causing high mortality and morbidity. The key treatment relies on the rapid intervention to dissolve thrombus, to reduce bleeding side effect and re-canalize clotted blood vessels using clot lysis drugs. Tissue plasminogen activator (tPA) is the only FDA-approved drug for ischemic stroke, but it has many limitations in clinical use. In recent years, the development of thrombolytic drugs and treatment strategies based on tPA has been progressed rapidly. Here we review the recent progress in this field, including the contributions from us and others, to promote the future development of novel thrombolytic drugs.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Investigación
/
Terapia Trombolítica
/
Isquemia Encefálica
/
Activador de Tejido Plasminógeno
/
Accidente Cerebrovascular
/
Fibrinolíticos
Límite:
Humanos
Idioma:
Chino
Revista:
Chinese Journal of Biotechnology
Año:
2020
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS